TG Therapeutics, Inc.

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell mediated diseases. Its primary marketed product is BRIUMVI, an anti-CD20 monoclonal antibody approved for adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The company also has a pipeline that includes Ublituximab IV, a glycoengineered anti-CD20 mAb for relapsing MS; TG-1701, an orally available Bruton's tyrosine kinase (BTK) inhibitor; and TG-1801, a bispecific CD47 and CD19 antibody. Additionally, TG Therapeutics has license agreements with LFB Biotechnologies, GTC Biotherapeutics, Ildong Pharmaceutical, and Jiangsu Hengrui Medicine.

TG Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol TGTX. The company trades in United States Dollars (USD). As a Nasdaq-listed company, it is subject to the reporting and regulatory requirements of the U.S. Securities and Exchange Commission (SEC). Investors can buy and sell shares of TGTX through most major brokerage platforms that offer access to U.S. stock exchanges.

TG Therapeutics operates in the Healthcare sector and specifically within the Biotechnology industry. As a biotechnology company, it focuses on research, development, and commercialization of therapies for diseases, particularly those involving B-cells. The company's work in monoclonal antibodies and small molecule inhibitors places it at the forefront of targeted treatments for multiple sclerosis and other B-cell mediated conditions. Biotechnology companies like TG Therapeutics typically invest heavily in research and development to bring innovative drugs to market.

TG Therapeutics, Inc. is headquartered in Morrisville, North Carolina, United States. The company serves markets in the United States and globally. Its commercial product BRIUMVI is available for patients in the U.S., and the company has license agreements with international partners such as LFB Biotechnologies in France, Ildong Pharmaceutical in South Korea, and Jiangsu Hengrui Medicine in China, indicating a global reach. The company was incorporated in 1993 and has since evolved into a commercial-stage biopharmaceutical entity with a focus on B-cell mediated diseases.

TG Therapeutics generates revenue primarily through the commercialization of its approved product BRIUMVI, an anti-CD20 monoclonal antibody for relapsing forms of multiple sclerosis. As a commercial-stage company, its revenue comes from sales of this drug in the U.S. market. Additionally, the company may receive milestone payments or royalties from its license agreements with partners like LFB Biotechnologies, GTC Biotherapeutics, Ildong Pharmaceutical, and Jiangsu Hengrui Medicine. The company's pipeline, including Ublituximab IV, TG-1701, and TG-1801, represents potential future revenue sources if these candidates receive regulatory approval.